

Arthralgias/myalgias associated with targeted therapy for CLL/SLL/MCL

References

1. Byrd JC, Brown JR, O'Brien S, et al; RESONATE Investigators. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*. 2014;371(3):213-223.
2. Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. *Blood Adv*. 2019;3(12):1799-1807.
3. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. *Lancet*. 2020;395(10232):1278-1291.
4. Ghia P, Pluta A, Wach M, et al. Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results. *J Clin Oncol*. 2020;38(15 suppl):8015-8015.
5. Rhodes J, LoRe VA, Mato AR, et al. Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. *Clin Lymphoma Myeloma Leuk*. 2020;20(7):438-444.e1.
6. Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis. *Haematologica*. 2018;103(5):874-879.
7. Ghasoub R, Albattah A, Elazzazy S, et al. Ibrutinib-associated severe skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia – case report and literature review. *J Oncol Pharm Pract*. 2020;26(2):487-491.
8. Bennett C. Ibrutinib may impair natural killer cell cytotoxic activity, study suggests. *Cancer Therapy Advisor*. June 19, 2019. <https://www.cancertherapyadvisor.com/home/cancer-topics/lymphoma/ibrutinib-for-mantle-lymphoma-mcl-may-impair-naturalcyto-toxic-activity/>. Accessed July 19, 2020.
9. Patel V, Balakrishnan K, Bibikova E, et al. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. *Clin Cancer Res*. 2017;23(14):3734-3743.
10. Shaw ML. Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects. *AJMC*. 2020;26(7):SP226-SP227.
11. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. *J Clin Oncol*. 2021 July 26 [Epub ahead of print].

12. Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of ALPINE study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. EHA 2021 Virtual Congress. Abstract LB1900. Presented June 11, 2021.
13. Kater A, Owen C, Moreno C, et al. Fixed duration ibrutinib and venetoclax versus chlorambucil plus obinutuzumab for first-line chronic lymphocytic leukemia: Primary analysis of the phase 3 GLOW study. European Hematology Association 2021 Virtual Congress. Abstract LB1902. Presented June 12, 2021.
14. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. *Lancet*. 2021;397(10277):892-901.